



Atty Docket No: US-CH02.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)

Ma et al.)

Serial No.: 09/801,115)

Filed: March 7, 2001)

For: Chemokine-Like Factors (CKLFs) With)
Chemotactic And Hematopoietic)
Stimulating Activities)

Date: November 30, 2002

Group Art Unit: 1647

Examiner: Bridget E. Bunner

#15
A.G.
12/17/02

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

TRANSMITTAL OF MISSING REFERENCES
FOR PREVIOUSLY SUBMITTED
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

Applicants respectfully submit the copies of two references (No. AG and AK) which the Examiner maintains were missing from the original Information Disclosure Statement submitted on July 6, 2001, and an English abstract of reference No. AE (CN 1202906) and EP 0860446A1 which is the equivalent of CN 1202906.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail mailing label number EK950433940US

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Box PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231.

on 11/30/2002

Typed or printed name of person signing this certificate

Yi Li

Signature [Signature]

The undersigned states that the references being provided are the same ones that were cited to the Patent and Trademark Office before the mailing date of a first Office action on the merits of the above-referenced patent application and are being provided to the Examiner within the period of time for response to the notice of missing references. Accordingly, Applicants maintain that in accordance with 37 CFR 1.97(b)(3) no fee is required to be paid upon the filing of this Information Disclosure Statement.


The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A PTO 1449 Form listing these missing references, along with copies of the references, is enclosed. The Examiner is respectfully requested to make of record these references.


Respectfully submitted,

Date: 11/30/2002

By: 
Yi Li
Registration No. 44,211
Agent for Applicant
Telephone: (786) 242-9349

Please address all correspondence to:

CUSPA Technology Law Associates
11820 SW 107 Ave.
Miami, FL 33176



RECEIVED

DEC 05 2002

TECH CENTER 1600/2000 1 of 1

Form PTO-1449 U.S. Department of Commerce
Patent and Trademark OfficeAttorney Docket No.
US-CH02,02Serial No.
09/801,115**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Applicant: Ma, et al.

Filing Date: 3/7/2001

Group: 1647

U. S. PATENT DOCUMENTS

Examiner Initial	Ref	Document Number	Date	Name	Class	Sub-Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Ref	Document Number	Date	Country	Class	Sub-Class	Translation	
							Yes	No
	AE	CN 1202906 EP 0860446A1, equivalent of CN 1202906	12/23/1998	China			-- Abstract	-- English document

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AG	Brantschen et al. 1989, "Differential Expression of Cytokine mRNAs in Human Cell Lines", Lymphkine Research, 2(3) 163-72.
	AK	Marshall et al., 1998 "HGS launches "first" genomics product in clinic", Nature Biotechnology, 16 (2): 120.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if citations considered, whether or not citation is in conformation with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.